Life Science Investing Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
Life Science Investing Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
Life Science Investing Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
Life Science Investing Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
Life Science Investing Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome
Life Science Investing Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
Life Science Investing Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635
Life Science Investing Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
Life Science Investing Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Life Science Investing Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
